Live Biotherapeutics Drug Discovery Service for Irritable Bowel Syndrome (IBS)
Since its inception, Creative Biolabs has been dedicated to developing high-quality solutions that promote innovation. We have a strong reputation for accuracy, efficiency, and consistency in our product and project delivery standards.
Overview of Irritable Bowel Syndrome (IBS)
IBS is a brain-gut disorder characterized by chronic abdominal pain and discomfort. Disturbed microbiota profiles are associated with co-morbidities of IBS, including cognitive changes, anxiety, and depression, indicating the gut microbiota's potential to contribute to IBS symptoms as well as serve as a therapeutic target. Probiotics are also used in IBS because they are attractive treatments for IBS given their safety profile and multiple mechanisms of action.
Fig.1 An overview of suggested mechanisms and factors involved in IBS.1
Probiotics for IBS
The use of probiotics is one way to treat IBS because of their potential to ameliorate dysbiosis or stabilize the host microbiome. By normalizing the ratio of interleukin (IL)-10/IL-12 produced by monocytes, probiotics have a good effect on stabilizing the intestinal flora and regulating the immune response in patients with IBS. Escherichia coli Nissle 1917 has been shown to improve colonic contractility, while Bacteroides thetaiotaomicron has been shown to alter the expression of neurally related genes.
Regarding B. lactis, it has been shown to reduce maximal abdominal distension, orocecal and colonic transit times, abdominal pain/discomfort, and global IBS symptoms in female IBS-C patients. B. animalis probiotics have been shown in IBS-C patients to improve bloating within 3 weeks and to improve stool frequency within 6 weeks of treatment.
L. plantarium has been demonstrated to reduce flatulence and improve stool frequency after 4 weeks of treatment in IBS patients. In the treatment of children with IBS or functional pain, Lactobacillus rhamnosus has been shown to reduce the frequency and severity of abdominal pain. Treatment with L. casei has been shown to improve stool frequency and consistency in adult IBS and SIBO patients. L. reuteri has also been studied in the treatment of IBS.
Improvement in abdominal pain/discomfort has been reported in Saccharomyces cerevisiae and S. boulardi yeast strains in IBS patients.
Mechanisms of Probiotics in IBS
-
Inhibition of Pathogen Binding
-
Enhanced Barrier Function
-
Immune Function
|
-
Colonic Transit and Motility
-
Effect on Intraluminal Milieu
-
Alterations in Visceral Hypersensitivity
|
Next-generation Probiotic Strains at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the Following Type/Similar IBS Research
|
Research Article
|
Available Services
|
|
Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model.2
|
-
Probiotics treatment
-
Cytokine analysis
-
Lactobacillus-macrophage bioassays and evaluation of probiotic antagonism
-
Determination of bacterial colonization
-
Cytokine quantitation
|
|
The Lactobacillus gasseri G098 strain mitigates symptoms of DSS-induced inflammatory bowel disease in mice.3
|
-
Quantification of inflammatory cytokines in the serum
-
Fecal DNA extraction, sequencing, and analysis
|
Creative Biolabs is a leading contract research services company. Our integrated solutions from isolation and screening of probiotics to functional studies make us the preferred partner for pharmaceutical and biotech companies in custom analytical development and next-generation probiotics candidate strains discovery. If you are interested in our products and services in the area of live biotherapeutics, please do not hesitate to contact us for more details.
References
-
Dale, Hanna Fjeldheim, and Gülen Arslan Lied. "Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives." Turkish Journal of Medical Sciences 50.10 (2020): 1632-1641.
-
Hong, Ki-Bae, et al. "Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model." BMC complementary and alternative medicine 19 (2019): 1-8.
-
Zhang, Wei-Qin, et al. "The Lactobacillus gasseri G098 strain mitigates symptoms of DSS-induced inflammatory bowel disease in mice." Nutrients 14.18 (2022): 3745.
-
Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
